Prescription drug abuse is emerging as a public health challenge among Indian youth. Critically evaluate the adequacy of Schedule H1 provisions in addressing this.

Q. Prescription drug abuse is emerging as a public health challenge among Indian youth. Critically evaluate the adequacy of Schedule H1 provisions in addressing this. (15 marks, 250 words)

The reclassification of Pregabalin under Schedule H1 of the Drugs Rules, 1945, prompted by state reports of misuse among youth for its sedative and euphoric effects [1], signals a regulatory shift toward controlling prescription-drug abuse. Schedule H1 offers meaningful safeguards, yet its adequacy against organised youth misuse remains contested.

Strengths of Schedule H1 - Prescription-only sale: dispensing solely against a Registered Medical Practitioner's prescription curbs casual over-the-counter access [1]. - Traceability: a mandatory separate register recording prescriber, patient and quantity, retained for three years, deters diversion and aids enforcement [2]. - Visibility: the compulsory "Schedule H1 Drug Warning" label sensitises consumers [1]. - Proportionate tool: it controls misuse-prone but therapeutically vital drugs (chronic pain, neuropathy, fibromyalgia) without the criminalisation of the NDPS Act, 1985, preserving genuine patient access [1].

Limitations - Weak enforcement: originally applied to 46 drugs in 2014 to check antimicrobial resistance [2], compliance stayed poor as state drug-control administrations lack inspectors to audit registers. - Reactive, not preventive: scheduling followed misuse reports rather than pre-empting it [1]. - Supply-side gaps: illegal stocking, online pharmacies and counterfeit channels bypass retail controls. - Demand-side blindness: it ignores the psychosocial drivers of youth addiction.

Schedule H1 is a necessary and rights-sensitive first step, but insufficient alone. Coupling it with CDSCO-led enforcement audits, digitised prescription tracking, and youth de-addiction programmes would align the regime with SDG-3 goals of health and well-being, converting a paper safeguard into effective public-health protection.

(~250 words)

Sources: 1. Union Health Ministry Brings Pregabalin Under Schedule H1 (PIB, 2026) — Pregabalin's H1 reclassification, misuse among youth, prescription/register/label conditions, therapeutic uses 2. Rules for Selling of Drugs Under Schedule H1 (PIB) — 2013 origin covering 46 drugs, separate register, three-year record retention